Related Experiment Video
Updated: Sep 15, 2025
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Selective Serotonin Reuptake Inhibitor Fluoxetine Alters Gene Expression Patterns of Sarcoma and Significantly
Krishna Mahanti1, Jayasree Saha1,2, Debanjan Sarkar1,3
1Immunobiology and Translational Medicine Laboratory, Department of Zoology, Sidho Kanho BirshUniversity, Purulia 723104, India.
The effectiveness of cancer therapy is significantly hindered by immunosuppressive mechanisms within the tumor microenvironment (TME). Immunotherapy for cancer leverages the body's immune system, Enhanced immune response to identify, attack, and eliminate tumor cells is the primary goal of immunotherapy. Immune checkpoint blocking, adoptive cell therapy, and cytokine and monoclonal antibody treatments have been reported to achieve significant success in cancer therapy. However, their effectiveness may vary, and immune-related side effects remain a major challenge. In this study, we evaluated the immunomodulatory properties of the selective serotonin reuptake inhibitor (SSRI) fluoxetine. It has been previously reported that fluoxetine exhibits anti-inflammatory properties and has limited effects against cancer; however, a detailed systematic study of the effects of fluoxetine on tumor growth, survival, and the host immune system has not been undertaken. This study evaluates the therapeutic potential of fluoxetine in sarcoma-bearing animals and explores the underlying mechanisms of action. Fluoxetine treatment in vitro showed minimal effects on sarcoma proliferation or survival; however, microarray-based gene expression analysis revealed the induction of a number of genes and pathways related to immune regulations in fluoxetine-treated sarcoma cells. These findings are consistent with the results of our in-silico analysis of fluoxetine target genes in myeloid lineage cells in the TME. Treatment with fluoxetine significantly reduced tumor burden in vivo. The observed antitumor effects were driven by modulation of the tumor microenvironment, including reduced the immunosuppressive properties of myeloid lineage cells and restored the number and activation of cytotoxic T cells. These findings demonstrate fluoxetine as a potential novel adjunct therapy for cancer, worthy of further preclinical and clinical investigations.
The effectiveness of cancer therapy is significantly hindered by immunosuppressive mechanisms within the tumor microenvironment (TME). Immunotherapy for cancer leverages the body's immune system, Enhanced immune response to identify, attack, and eliminate tumor cells is the primary goal of immunotherapy. Immune checkpoint blocking, adoptive cell therapy, and cytokine and monoclonal antibody treatments have been reported to achieve significant success in cancer therapy. However, their effectiveness may vary, and immune-related side effects remain a major challenge. In this study, we evaluated the immunomodulatory properties of the selective serotonin reuptake inhibitor (SSRI) fluoxetine. It has been previously reported that fluoxetine exhibits anti-inflammatory properties and has limited effects against cancer; however, a detailed systematic study of the effects of fluoxetine on tumor growth, survival, and the host immune system has not been undertaken. This study evaluates the therapeutic potential of fluoxetine in sarcoma-bearing animals and explores the underlying mechanisms of action. Fluoxetine treatment in vitro showed minimal effects on sarcoma proliferation or survival; however, microarray-based gene expression analysis revealed the induction of a number of genes and pathways related to immune regulations in fluoxetine-treated sarcoma cells. These findings are consistent with the results of our in-silico analysis of fluoxetine target genes in myeloid lineage cells in the TME. Treatment with fluoxetine significantly reduced tumor burden in vivo. The observed antitumor effects were driven by modulation of the tumor microenvironment, including reduced the immunosuppressive properties of myeloid lineage cells and restored the number and activation of cytotoxic T cells. These findings demonstrate fluoxetine as a potential novel adjunct therapy for cancer, worthy of further preclinical and clinical investigations.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:23Antidepressant Drugs: MAOIs and Other Agents
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists